Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination

Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = 1.101.401.77, p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = 0.440.921.93, p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = 1.382.635.00, p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3. Solid organ transplant recipients with negative anti‐spike antibody after a two‐dose mRNA SARS‐CoV‐2 vaccine series are more likely to seroconvert after receiving a third dose of the heterologous vaccine Ad.26.COV2.S, compared to a homologous mRNA vaccine.